MenQuadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and Y.
Invasive meningococcal disease (IMD) is associated with a significant risk of death and severe sequelae. 50% of IMD cases are fatal if left untreated and even when the disease is diagnosed and treated early, 8-15% IMD patients will die. Sequelae such as neurological and hearing impairment or amputation occur in up to 20% of survivors.1,2
IMD remains a serious threat in the UK and abroad. In the meningitis belt of sub Saharan Africa, seasonal hyperendemicity is observed every dry season with weekly incidence rates rising to up to 10/100,000 population.3,4 IMD epidemics have also been linked to Islamic pilgrimages to Makkah, resulting in importations of IMD to the UK. 5 Globally, specific serogroups can shift unpredictably within regions over time.6-9
MenQuadfi is designed to help protect individuals aged 12 months and older against IMD caused by serogroups A, C, W and Y.
It is the only MenACWY conjugate vaccine in Europe available in a fully liquid formulation.10,11 This can potentially save time and reduce reconstitution errors.12
uses a tetanus toxoid carrier protein, which is
T-cell dependant immune system.13
High seroprotection has been demonstrated with MenQuadfi across all licensed age groups and all 4 serogroups (A,C,W,Y). In clinical trials, the safety of MenQuadfi was shown to be similar to comparator vaccines.14-17
A MenACWY certificate will be provided on ordering MenQuadfi
|Presentation||Schedule||Further doses||Age range|
|1 single dose vial (0.5mL)||1 dose||A single 0.5mL dose may be used to boost subjects who have previously received a meningococcal vaccine containing the same serogroups.||12 months+|
Sanofi Pasteur is committed to providing you and your patients with a comprehensive range of support materials, including disease awareness patient leaflets and in-surgery display items.
• Simply visit https://sanofi.medisa.com
• Select the user group which best describes your role in your organisation
• Narrow your search by selecting the appropriate disease area
• Select which materials you would like to receive and how many
• Log-in or register to create an account
• Confirm your order
Date of preparation: September 2021 | MAT-GB-2103587(v1.0)